Results 101 to 110 of about 260,886 (316)
, 2017 Yes-associated protein (YAP) is a downstream target of the Hippo pathway and has been found to be oncogenic driving many cancers into developing metastatic phenotypes leading to poor survival outcomes.
Mcgowan, Marc Kevin +4 more
core +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Advanced Science, EarlyView.Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs [PDF]
Journal of Pharmacy & Pharmacognosy ResearchContext: Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer type, with 80-85% prevalence. Usually, NSCLC is treated by chemotherapy and radiotherapy in collaboration with gefitinib or other anticancer drugs.
Precella Silvia +2 more
doaj +1 more source
MET overexpression and gene amplification in NSCLC: a clinical perspective
, 2013 Lorenza Landi, Gabriele Minuti, Armida D'Incecco, Jessica Salvini, Federico CappuzzoMedical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, ItalyAbstract: The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET)
D'Incecco A +4 more
core
Novel Biological Therapy in Non-small Cell Lung Cancer
, 2023 This thesis discusses the epidemiology, risk factors, diagnosis, staging, aetiology, classification and treatment of Non small-cell lung cancer (NSCLC), specifically delving into the novel biological therapies being used and researched today. This thesis
Alawad, Mohamed
core
Advanced Science, EarlyView.AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer [PDF]
Context: The significant survival benefit of chemotherapy over best supportive care for locally advanced and metastatic NSCLC has been amply demonstrated in the literature.
Paul Rebattu +8 more
core
Advanced Science, EarlyView.This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
, 2013 GJM Herder,1 H Codrington,2 CD Colder,3 JG Aerts4,51St Antonius Hospital, Nieuwegein, The Netherlands; 2Haga Hospital, The Hague, The Netherlands; 3St Jansdal Hospital, Harderwijk, The Netherlands; 4Amphia Hospital, Breda; 5Erasmus MC Rotterdam, The ...
Aerts JG +3 more
core
Advanced Science, EarlyView.Icariin promoted the growth of Akk by enhancing the activity of N‐acetylgalactosaminidase (Amuc_0920), which enhanced mucin utilization and provided a favorable nutrient environment for bacterial growth. This icariin‐mediated enrichment of Akk further reshaped the tumor microenvironment and promoted CD8+ T cell infiltration, ultimately synergizing with
Shuangying Qiao +12 more
wiley +1 more source